A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Latest Information Update: 24 Aug 2024
At a glance
- Drugs Blinatumomab (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Dasatinib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Mesna (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Ponatinib (Primary) ; Prednisone (Primary) ; Vincristine (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 17 Mar 2023 Status changed from active, no longer recruiting to recruiting.
- 16 Feb 2023 Status changed from suspended to active, no longer recruiting.
- 31 Dec 2022 Status changed from recruiting to suspended. (FDA Partial Clinical Hold)